The National Center for Advancing Translational Sciences (NCATS) has several open SBIR and STTR program funding opportunities designed to help advance and commercialize translational research technologies. NCATS encourages applications in these research areas of interest: drug discovery and development, diagnostics and devices, bioinformatics and information technology, and clinical research.
Register today for NCATS’ webinar on Nov. 10, 2015, 1:00 p.m. ET, co-hosted by the Coalition of State Bioscience Institutes Entrepreneurship Committee, to learn more about the following funding opportunities.
Benefits of Applying: Funding is stable, predictable, not a loan, and non-dilutive. Small businesses retain intellectual property rights, and awardees also are eligible to access other support programs designed to help small businesses commercialize their technologies.
Current Funding Opportunities
All have an application deadline of Jan. 5, 2016, 5:00 p.m. local time:
2015 Omnibus Solicitation
Small businesses, research and technology transfer organizations are eligible to apply for the 2015 Omnibus Solicitation. Applications may address any stage of translation, from target validation through pre-clinical and clinical evaluation to intervention, implementation and dissemination.
SBIR Direct to Phase II
Small businesses that have accomplished the objectives of a Phase I SBIR grant through non-SBIR funds are able to apply for SBIR direct to Phase II funding. Applicants must demonstrate the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential.
- PAR-15-288: Direct Phase II SBIR Grants to Support Extended Development, Hardening, and Dissemination of Technologies in Biomedical Computing, Informatics, and Big Data Science
- PAR-14-088: Direct Phase II SBIR Grants to Support Biomedical Technology Development
Platform Delivery Technologies for Nucleic Acid Therapeutics
This funding opportunity is designed to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.
Development of Appropriate Pediatric Formulations and Drug Delivery Systems
Applications must address different and complementary research needs for the development of appropriate pediatric drug formulations in different age groups.
NCATS’ SBIR and STTR programs are engines of innovation for developing and commercializing tools, technologies and intervention platforms to support the creation of new therapeutics and diagnostics. SBIR and STTR are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.